April 1, 2013

Pittsfield –Patrick Muraca, the president & CEO of biomarker pioneer Nuclea Biotechnologies, Inc. today announced that he has been appointed to the Jimmy Fund Visiting Committee. The Jimmy Fund Visiting Committee is one of eight prestigious “blue ribbon” committees at Dana-Farber. Each of the committees consists of individuals who are leaders in their community, in business, and in academia. The committee members are able to offer their thoughts, opinions, and strategic advice on Dana-Farber’s research, patient care, and fundraising efforts.

Over the years, Pat has been involved in supporting the Jimmy Fund in a number of capacities. Pat serves on the board of the Jimmy Fund Council of the Berkshires, which has   raised over one million dollars over the past six years.   Pat was the recipient of two Jimmy Fund of Berkshire County – Dana-Farber Appreciation Awards. Most recently, Nuclea established and funded Dr. Massimo F. Loda as the Paul M. Dowd Chair in Molecular Oncologic Pathology, creating Dana Farber’s first Chair of Pathology.  The position will help to further advance Dr. Loda’s research into the prevention, detection, and treatment of cancer. 

“I am truly honored to be appointed to the Jimmy Fund Visiting Committee,” said Pat Muraca. “Dana-Farber and the Jimmy Fund allow for ground-breaking cancer research to take place. As a fellow scientist in the cancer field, I am humbled by the offer and I look forward to helping in any way that I can.”

Suzanne Fountain, Director of the Jimmy Fund, said, “We are so pleased to have Pat join us as a member of the Visiting Committee for the Jimmy Fund.  His contributions to this committee will be of great importance and we are grateful that he is willing to support us in this manner, as well as the myriad other ways he has already shown such generosity to Dana-Farber and the Jimmy Fund.”


Nuclea Biotechnologies, Inc is headquartered in Pittsfield, Massachusetts. Nuclea has three lines of business, each of which is operated by a separate wholly-owned subsidiary: Nuclea Diagnostic Laboratories (“NDL”) which has developed and is commercializing unique diagnostic tests for colon, breast, leukemia, lung and prostate cancer; Nuclea Biomarkers (“NBM”) which performs research leading to novel molecular oncology therapeutics and diagnostics for the pharmaceutical and biotechnology industries and performs services by analyzing and testing the efficacy and validating other indications of existing therapeutics utilizing a highly characterized and consented patient database; and Nuclea Biotherapeutics (“NBT”) which develops novel therapeutics.

About Dana-Farber Cancer Institute

Dana-Farber Cancer Institute ( is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute. It provides adult cancer care with Brigham and Women’s Hospital as Dana-Farber/Brigham and Women’s Cancer Center and it provides pediatric care with Boston Children’s Hospital as Dana-Farber/Children’s Hospital Cancer Center. Dana-Farber is the top ranked cancer center in New England, according to U.S. News & World Report, and one of the largest recipients among independent hospitals of National Cancer Institute and National Institutes of Health grant funding. Follow Dana-Farber on Facebook: and on Twitter: @danafarber.

About the Jimmy Fund

The Jimmy Fund ( solely supports Boston’s Dana-Farber Cancer Institute, raising funds for adult and pediatric cancer care and research to improve the chances of survival for cancer patients around the world.  This year celebrates the 60th anniversary of the Jimmy Fund and Boston Red Sox relationship, and represents one of the most remarkable partnerships between a team and a charity in the history of professional sports. The Jimmy Fund is also the official charity of the Massachusetts Chiefs of Police Association, the Pan-Massachusetts Challenge, and the Variety Children's Charity of New England. Since 1948, the generosity of millions of people has helped the Jimmy Fund save countless lives and reduce the burden of cancer for patients and families worldwide. Follow the Jimmy Fund on Facebook: and on Twitter: @TheJimmyFund.

# # #



Gregory M. D’Agostino

Chief Operating Officer

4 Liberty Square, 5th Floor, Boston, MA 02109

Office: 617.695.0369  |  Mobile: 617.388.6477


Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.